GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
| Revenue (TTM) | $33.20B |
| Gross Profit (TTM) | $24.40B |
| EBITDA | $10.82B |
| Operating Margin | 30.90% |
| Return on Equity | 33.40% |
| Return on Assets | 10.00% |
| Revenue/Share (TTM) | $16.51 |
| Book Value | $11.83 |
| Price-to-Book | 4.17 |
| Price-to-Sales (TTM) | 2.99 |
| EV/Revenue | 2.648 |
| EV/EBITDA | 9.09 |
| Quarterly Earnings Growth (YoY) | -69.50% |
| Quarterly Revenue Growth (YoY) | 5.30% |
| Shares Outstanding | $2.00B |
| Float | $1.94B |
| % Insiders | 0.06% |
| % Institutions | 17.48% |
Volatility is currently contracting
President Donald Trump's latest executive order calls for splitting the measles, mumps and rubella, or MMR, vaccine into three separate shots. But doctors and other experts say that effort has no scientific basis and is unlikely to get off the ground.
Vaccine maker GlaxoSmithKline Pharmaceuticals reported a 15.7% rise in first-quarter profit on Monday, aided by stable demand across its vaccine and drug portfolio, including respiratory and specialty medicines.
British biotech firm Relation Therapeutics said on Wednesday it had entered into a research collaboration with GSK worth up to $110 million to generate human cellular datasets and train AI models for identifying potential new drug targets.
GSK beats Q2 earnings and revenue estimates, reaffirms 2026 guidance and unveils a new cost-saving plan.
GSK plc (GSK) Q2 2026 Earnings Call Transcript
GSK NYSE: GSK reported second-quarter sales growth of 5% at constant exchange rates to more than £8.4 billion, supported by Specialty Medicines and Vaccines, while outlining a new cost-savings and investment program intended to accelerate its late-stage pipeline and support growth beyond 2031.
GSK delivered healthy Q2 and H1 2026 results, with the highlight being core turnover and EPS growth at the upper end of the guidance ranges. However, it's hard to make a Buy case for it anymore as stock metrics like the forward P/E and dividend yield don't offer adequate support. While the company has maintained its long-term sales target, even that isn't encouraging enough from the stock price perspective as only limited price returns are foreseen.
GSK PLC (LSE:GSK, NYSE:GSK) shares jumped to a three-month high after the drugmaker beat second-quarter expectations across its main measures and accelerated investment in its pipeline. Revenue rose 5% to £8.41 billion, ahead of the £8.25 billion City consensus.
GSK (GSK) came out with quarterly earnings of $1.36 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.23 per share a year ago.
The U.K. drugmaker is targeting annual savings of $2.52 billion by 2029, as Chief Executive Luke Miels outlined his roadmap to hit the company's 2031 sales target.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GSK and any ticker you trade — then tracks every position and per-strategy win rate.
